Craig Ellis

Dan Moore

Daniel Moore

David Silver

- **ROG** reported **Q3 2025 net sales of $216.0 million** and **adjusted earnings per diluted share of $0.90**, with both results at the high-end of guidance.  **[0000084748_2212672:7]** **[0000084748_2212672:8]** 
- The company achieved an **Adjusted EBITDA margin of 17.2%** and generated **$21 million of free cash flow** in Q3 2025.  **[0000084748_2212672:7]** **[0000084748_2212672:8]** **[0000084748_2212672:9]** 
- For **Q4 2025**, **ROG** anticipates **net sales between $190 million and $205 million** and **adjusted earnings per diluted share between $0.40 and $0.80**.  **[0000084748_2212672:9]** 
- The Q4 outlook projects a sequential decline in sales due to normal seasonality, with an expected adjusted EBITDA margin of **15%**.  **[0000084748_2212672:7]**

ROG Reports Q3 2025 Results and Provides Q4 2025 Guidance

- Rogers Corporation reported **Q3 2025 sales** at the upper end of guidance, increasing **6.5% sequentially** and **2.7% year-over-year**, with **adjusted EPS of $0.90**.  **[0000084748_2212865_1]** **[0000084748_2212865_3]** 
- For **Q4 2025**, the company projects sales between **$190 million and $205 million**, representing a **3% year-over-year increase** at the midpoint, and anticipates **adjusted EPS between $0.40 and $0.80**.  **[0000084748_2212865_3]** **[0000084748_2212865_4]** 
- **Adjusted EBITDA margin** improved by **540 basis points sequentially to 17.2%** in Q3 2025 and is guided to improve by **300 basis points year-over-year** at the midpoint in Q4 2025.  **[0000084748_2212865_3]** **[0000084748_2212865_4]** 
- Production commenced at the new **ceramic facility in China** in Q3, which is anticipated to create an **80 basis point headwind** to Q4 gross margin due to ramp-up costs.  **[0000084748_2212865_1]** **[0000084748_2212865_3]** 
- The company is targeting **$13 million in annualized savings** from German ceramic operations restructuring by late 2026 and expects **Q4 share repurchases to exceed Q3 levels**, with **$66 million remaining** on the current program.  **[0000084748_2212865_1]** **[0000084748_2212865_3]** **[0000084748_2212865_4]**

Rogers Corporation Reports Q3 2025 Results and Provides Q4 2025 Outlook

- Rogers Corporation reported **net sales of $216.0 million** for Q3 2025, representing a **6.5% sequential increase**.  **[84748_0000084748-25-000064_q32025resultsannouncement.htm:0]** 
- **GAAP diluted earnings per share** for Q3 2025 were **$0.48**, a significant improvement from **$(4.00) in the prior quarter**, with **adjusted earnings per diluted share** reaching **$0.90**.  **[84748_0000084748-25-000064_q32025resultsannouncement.htm:0]** 
- The company's **gross margin** for Q3 2025 was **33.5%**, an increase of **190 basis points sequentially**.  **[84748_0000084748-25-000064_q32025resultsannouncement.htm:0]** 
- For Q4 2025, Rogers Corporation anticipates **net sales** to be between **$190 million and $205 million**, and **adjusted earnings per diluted share** to range from **$0.40 to $0.80**.  **[84748_0000084748-25-000064_q32025resultsannouncement.htm:0]**

Rogers Corporation Announces Third Quarter 2025 Results and Q4 2025 Outlook

- Rogers Corporation reported **net sales of $216.0 million** for the third quarter of 2025, marking a **6.5% sequential increase**.  **[84748_3dc3db64a52145cda815bd7767b7b92e_0]** 
- **GAAP earnings per share** for Q3 2025 were **$0.48**, a significant improvement from $(4.00) in the prior quarter, while **adjusted earnings per share** rose to **$0.90** from $0.34 sequentially.  **[84748_3dc3db64a52145cda815bd7767b7b92e_0]** 
- The company's **gross margin** increased by **190 basis points sequentially** to **33.5%** in Q3 2025.  **[84748_3dc3db64a52145cda815bd7767b7b92e_0]** 
- For the fourth quarter of 2025, Rogers Corporation anticipates **net sales** to be in the range of **$190 million to $205 million** and **adjusted earnings per diluted share** between **$0.40 and $0.80**.  **[84748_3dc3db64a52145cda815bd7767b7b92e_1]** 
- In Q3 2025, **net cash provided by operating activities** was **$28.9 million**, and **free cash flow** was **$21.2 million**, with **share repurchases totaling $10.0 million**.  **[84748_3dc3db64a52145cda815bd7767b7b92e_1]**

Rogers Corporation Reports Third Quarter 2025 Results

- **Genentech**, a member of the Roche Group, announced positive results from two Phase III studies (MEERKAT and SANDCAT) for its investigational drug **vamikibart** in uveitic macular edema (UME).  **[84748_2dac45f7d38f4f7581e7fe63f24244da_0]** 
- Vamikibart, a potential **first-in-class non-steroid targeted therapy**, demonstrated rapid improvements in vision and reductions in macular thickness.  **[84748_2dac45f7d38f4f7581e7fe63f24244da_0]**  The MEERKAT study achieved **statistically significant superiority** over sham for the primary endpoint of vision improvement.  **[84748_2dac45f7d38f4f7581e7fe63f24244da_1]** 
- The drug was generally **well tolerated**, with a low incidence of treatment-related ocular adverse events, addressing a significant unmet need given the side effects of current steroid treatments for UME.  **[84748_2dac45f7d38f4f7581e7fe63f24244da_0]** **[84748_2dac45f7d38f4f7581e7fe63f24244da_1]** 
- Genentech plans to discuss these data with **health authorities globally** for potential regulatory approval.  **[84748_2dac45f7d38f4f7581e7fe63f24244da_0]**

Genentech Announces Phase III Vamikibart Trial Results

- **Rogers Corporation** announced that **Peter Wallace**, Chair of the Board of Directors, will not stand for re-election at the Company’s 2026 Annual Meeting of Shareholders.  **[84748_02a8fea3ab6f408aab1e439780f4ca26_0]** 
- **Armand Lauzon**, an existing Board member since 2023, has been elected as the **new Chair**, effective immediately.  **[84748_02a8fea3ab6f408aab1e439780f4ca26_0]** 
- The company plans to appoint a **new independent director** to the Board with input from Starboard Value LP.  **[84748_02a8fea3ab6f408aab1e439780f4ca26_0]** 
- Following these changes, **Starboard Value** confirmed it does not intend to nominate directors for election at the Company’s 2026 Annual Meeting of Shareholders.  **[84748_02a8fea3ab6f408aab1e439780f4ca26_1]**

Rogers Corporation Announces Board Chair Transition and Plans for New Independent Director

- **Roche (ROG)** announced on **October 13, 2025**, that its **Elecsys pTau181 test** received **FDA clearance**, making it the **only blood-based biomarker test** indicated as an aid in the initial assessment for Alzheimer's disease in primary care.  **[84748_20251013DE95886:0]** 
- The test is intended for patients **aged 55 and older** presenting with cognitive decline, and its performance demonstrated a **97.9% negative predictive value (NPV)** for ruling out Alzheimer's pathology in early-stage, low-prevalence populations.  **[84748_20251013DE95886:0]** 
- This clearance is expected to **broaden patient access** to minimally invasive Alzheimer's testing, integrate primary care into the diagnostic pathway, and potentially **reduce the use of more invasive and costly procedures**.  **[84748_20251013DE95886:0]** **[84748_20251013DE95886:1]** 
- The Elecsys pTau181 test was **developed in collaboration with Eli Lilly and Company** and also recently received **CE Mark certification in Europe**.  **[84748_20251013DE95886:0]** **[84748_20251013DE95886:1]**

Roche's Elecsys pTau181 Test Receives FDA Clearance

- Roche's investigational drug combination of **giredestrant plus everolimus** demonstrated a significant improvement in **progression-free survival (PFS)** for patients with ER-positive, HER2-negative advanced breast cancer who had previously been treated with CDK4/6 inhibitors.  **[84748_f4ef97d5713941e1a9ac11680bd20e15]** 
- The **evERA Breast Cancer study** met its co-primary endpoints, making it the **first positive head-to-head trial** of an all-oral selective estrogen receptor degrader (SERD) regimen versus standard endocrine therapy.  **[84748_f4ef97d5713941e1a9ac11680bd20e15]** 
- While overall survival data are still immature, a **positive trend** favoring the giredestrant arm was observed, and the safety profiles were consistent with known effects without new concerns.  **[84748_f4ef97d5713941e1a9ac11680bd20e15]** 
- Following the announcement of these positive late-stage clinical trial results, **Roche's stock price increased by 1.5%** on the SIX Swiss Exchange.  **[84748_f4ef97d5713941e1a9ac11680bd20e15]**

Roche's Giredestrant Plus Everolimus Shows Positive Phase 3 Trial Results

- **Roche (ROG)** announced the integration of its **Accu-Chek SmartGuide** continuous glucose monitoring (CGM) solution with the **mySugr diabetes management app**, which has received **CE mark approval**.  **[84748_20250916SF73506:0]** 
- The **AI-enabled Accu-Chek SmartGuide** is the first CGM system to predict glucose levels up to **two hours ahead** and **seven hours overnight**, empowering proactive diabetes management.  **[84748_20250916SF73506:0]** 
- The solution is currently available in **13 countries** and is planned to expand to over **30 countries** across Europe, Latin America, and Asia-Pacific by year-end **2025**.  **[84748_20250916SF73506:0]** **[84748_20250916SF73506:1]** 
- Real-world evidence from the Accu-Chek SmartGuide rollout showed that using Night Low Predict reduced the likelihood of Level 1 hypoglycaemic events by **20%** and Level 2 hypoglycaemia by **31%** overnight.  **[84748_20250916SF73506:1]**

ROGERS (ROG)